[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100532247":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":17,"centralContacts":23,"locations":17,"responsibleParty":29,"collaborators":17,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":39,"eligibilityCriteria":40,"healthyVolunteers":35,"sex":41,"minAge":42,"maxAge":17,"enrollmentInfo":43,"targetDuration":17,"studyType":46,"phases":47,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":55,"whyStopped":17,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":17},{"fullName":5,"class":6},"Centre Hospitalier Universitaire Vaudois","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"Intervention arm","Adjustment of antidepressant treatment according to pharmacogenetic results obtained by genetic testing for cytochrome CYP 2C19 (alleles \\*2, \\*3 and \\*17)",[12],"Other: Prescription of escitalopram using pharmacogenetic testing",{"label":14,"type":15,"description":16,"interventionNames":17},"Control arm","NO_INTERVENTION","Delivery of escitalopram treatment as prescribed. Genetic analysis will be performed in batch at the end of the follow-up period.",null,[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":17},"Prescription of escitalopram using pharmacogenetic testing","Adjustment of escitalopram treatment according to pharmacogenetic results obtained by genetic testing for cytochrome CYP 2C19 (alleles \\*2, \\*3 and \\*17)",[9],[24],{"name":25,"role":26,"phone":27,"phoneExt":17,"email":28},"Chantal Csajka, Pre","CONTACT","+4121 314 42 63","chantal.csajka@chuv.ch",{"type":30,"investigatorFullName":31,"investigatorTitle":32,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"SPONSOR_INVESTIGATOR","Chantal Csajka","Professor","100532247","pharmacogenetic-testing-at-community-pharmacy-100532247",false,"NCT06210321","Pharmacogenetic Testing at Community Pharmacy","Randomised Controlled Study of the Efficacy and Acceptability of a Pharmacogenetic Test in the Management of Patients Treated With Escitalopram.","OffiGene","Inclusion Criteria:\n\n* Must consent to participate in the study,\n* Must sign consent,\n* Must be able to follow and understand the study procedures,\n* Initiation of escitalopram treatment for unipolar depression with or without anxiety\n\nExclusion Criteria:\n\n* Other condition than depression (such as panic disorder)\n* Escitalopram treatment already received\n* Not able to consent to participate in the study.","ALL","18 Years",{"count":44,"type":45},270,"ESTIMATED","INTERVENTIONAL",[48],"NA","The purpose of this study is to assess the clinical impact of reducing treatment failure rates after using genetic information targeting CYP2C19 in validating escitalopram prescription. 5 pharmacies in the canton of Vaud (Lausanne, Switzerland) will participate in the study.\n\nThe study will also explored the ability to perform the test in community pharmacy, physician and pharmacist approval of prescription changes, patient acceptance of the test and dose changes, the economic impact of the test, the association between genetic polymorphisms and therapeutic failures and the degree of satisfaction, barriers and facilitators by stakeholders.",[51],"Pharmacogenetic Testing",[53,54],"Community pharmacy","Escitalopram","NOT_YET_RECRUITING","2025-06-02",{"date":58,"type":59},"2025-06-05","ACTUAL",{"date":61,"type":45},"2025-08-15",{"date":63,"type":45},"2027-08-14",{"name":31,"class":6}]